Navigation Links
Chlamydia vaccine a step closer to reality

Scientists at Queensland University of Technology are one step closer to developing a world-first vaccine to protect women against contracting the most common sexually-transmitted disease, Chlamydia.

International vaccine company Sanofi-Pasteur has awarded QUT a funding boost of more than $300,000 to continue its research into Chlamydia and work towards developing a vaccine specifically targeting adolescent women.

Professor Peter Timms, from QUT's Institute of Health and Biomedical Innovation (IHBI), said a team of researchers had already identified certain proteins that were able to protect against Chlamydia infection.

"We've been testing these proteins as part of animal trials...and we think we've got the answer. It is possible that within three to five years we'll be finished the animal trials and be looking at clinical trials in humans."

Professor Timms said Sanofi-Pasteur's funding would allow QUT to evaluate the effectiveness of Chlamydia prevention methods developed at the university, as well as compare and test possible prevention methods being developed by Sanofi-Pasteur.

He said once a vaccine had been developed it could be administered via a patch, similar to ones used by smokers for nicotine.

"Patches are a good way to deliver proteins to a part of the body's immune system and they are also easy and user-friendly."

He said with rates of Chlamydia infection in some Australian communities as high as 12 per cent of the female population, there was a "real need" to develop a vaccine.

"Chlamydia is the most common infectious disease in the world and results in infertility in women and long-term chronic pelvic pain," he said.

"There are antibiotics to treat Chlamydia, but there's no vaccine to prevent it. In many cases women don't know they are infected because there are not really any physical signs or symptoms, so by and large they don't get treatment."

Professor Timms said Sanofi-Pasteur was one of the world's largest companies devoted to the development of human vaccines.

"The fact that such a large vaccine company as Sanofi-Pasteur has selected QUT to help develop Chlamydia vaccines points to the value of the work being done here," he said.

"Despite this current injection of funds, further work and funding is still needed to take this current research through to a vaccine product."

QUT researchers working on the project are part of IHBI's Cells and Tissue Domain and include Professors Peter Timms, Ken Beagley, Associate Professor Louise Hafner, Celia Berry and Chris Barker.


'"/>

Source:Queensland University of Technology


Related biology news :

1. Chlamydia parasite lives off our fat
2. Research advances quest for HIV-1 vaccine
3. A much-needed shot in the arm for HIV vaccine development
4. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
5. Gene vaccine for Alzheimers disease shows promising results
6. Influenza vaccine uses insect cells to speed development
7. Norovirus, AIDS vaccine and Hepatitis Virus
8. HIV vaccine trial breaks ground for future research
9. Live vaccines more effective against horse herpes virus
10. NIAID begins clinical trial of West Nile virus vaccine
11. Designing vaccines by computer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
(Date:5/3/2016)... Lithuania , May 3, 2016  Neurotechnology, ... released the MegaMatcher Automated Biometric Identification System ... of large-scale multi-biometric projects. MegaMatcher ABIS can process ... accuracy using any combination of fingerprint, face or ... MegaMatcher SDK and MegaMatcher Accelerator ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
Breaking Biology Technology: